// App-Quantinova.ai

563 : Combined treatment with PD-L1 blockade and a TLR7/8 agonist dramatically enhances antitumor immunity

Researchers

Presenter

  • Naoto Nishii

Principal Investigators

  • Yuta Kondo

  • Lixin Li

  • Walter Lau

  • Hiroyuki Harada

  • Miyuki Azuma

Medical Centers

  • Department of Molecular Immunology, Tokyo Medical and Dental University, Tokyo, Japan

  • Birdie Biopharmaceuticals, Inc., China

  • Department of Oral and Maxillofacial Surgery, Tokyo Medical and Dental University, Tokyo, Japan.

Locations

  • China

  • Japan

Companies

  • Birdie Biopharmaceut

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma

  • Colorectal Cancer

  • Skin carcinoma

  • Solid malignancies

Biomarkers

  • Cluster of differentiation 8A

  • Interleukin 1

  • Interleukin 6

  • Tumor necrosis factor

Drug/Treatment

  • Resiquimod

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved